Delving into the Latest Updates on Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd. with Synapse

概览

疾病领域	数量

肿瘤	2
内分泌与代谢疾病	1

排名前五的药物类型	数量

CAR-T	1
融合蛋白	1

排名前五的靶点	数量

MSLN(间皮素)	1
CD276(CD276抗原)	1

关联

2

项与 Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd. 相关的药物

CHT-102

靶点

MSLN

作用机制

MSLN抑制剂

在研机构

天津市肿瘤医院 [+1]

原研机构

天津市肿瘤医院

在研适应症

胰腺癌 [+1]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

CN117843809

专利挖掘

靶点

CD276

作用机制-

在研机构

Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.

原研机构

Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.

在研适应症

肿瘤

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

3

项与 Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd. 相关的临床试验

NCT06760364

/ Not yet recruiting临床1期IIT

A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer

Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer

开始日期2024-12-25

申办/合作机构

天津市肿瘤医院

[+1]

NCT06717022

/ RecruitingN/AIIT

A Clinical Study of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) for Mesothelin(MSLN) Positive Advanced Solid Tumors: a Single-arm, Open-label, Dose Escalation and Expansion Clinical Study

Objectives of Study：In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.

开始日期2024-05-06

申办/合作机构

天津市肿瘤医院

[+1]

NCT06730659

/ Recruiting临床1期IIT

A Single-Arm, Open-Label, Phase I Study of CHT101 for CD70-Positive Relapsed/Refractory Solid Tumors

Evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive advanced solid tumors.

开始日期2024-04-19

申办/合作机构

天津市肿瘤医院

[+1]